Capitalizing on HER2 receptor overexpression in cancers like breast and lung, HER2-targeting PDCs have also emerged as an impactful focus.108 For example, a Cyclo-GCGPep1 peptide was modeled after the trastuzumab-HER2 interface and conjugated it with CPT, creating a PDC with potent antiproliferative effects on HER2+ cells. The gene discussed is ERBB2; the disease is cancer.